Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: a scoping review.

Autor: Jeffers, Matthew S.^1,2 (AUTHOR), Xi, Cheng En¹ (AUTHOR), Bapuji, Raj¹ (AUTHOR), Wotherspoon, Hannah^1,3 (AUTHOR), Kimmelman, Jonathan⁴ (AUTHOR), Bedford, Patrick^5,6 (AUTHOR), McIsaac, Daniel I.⁷ (AUTHOR), Lalu, Manoj M.^1,2,7 (AUTHOR) mlalu@toh.ca, Fergusson, Dean A.^1,2,8 (AUTHOR) dafergusson@ohri.ca

Publikováno v: BMC Medicine. 10/23/2024, Vol. 22 Issue 1, p1-15. 15p.

Real-World evidence revelations: The potential of patient support programmes to provide data on medication usage.

Autor: Palffy, Eszter¹ (AUTHOR) eszter.palffy@novartis.com, Lewis, David John^2,3 (AUTHOR)

Publikováno v: PLoS ONE. 2/8/2024, Vol. 19 Issue 2, p1-13. 13p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study.

Autor: Walley RJ; UCB Pharma, 208 Bath Road, Slough, SL1 3WE, UK., Smith CL; Eli Lilly and Company Limited, Erl Wood Manor, Windlesham, GU20 6PH, UK., Gale JD; Pfizer, 610 Main Street, Cambridge, 02139, MA, USA., Woodward P; Pfizer, Neusentis, The Portway Building, Granta Park, Cambridge, CB21 6GS, UK.

Publikováno v: Pharmaceutical statistics [Pharm Stat] 2015 May-Jun; Vol. 14 (3), pp. 205-15. Date of Electronic Publication: 2015 Apr 10.

Delta Inflation, Optimism Bias, and Uncertainty in Clinical Trials.

Autor: Liu, Charles C., Wu, Peiwen, Yu, Ron Xiaolong

Publikováno v: Therapeutic Innovation & Regulatory Science; Nov2024, Vol. 58 Issue 6, p1180-1189, 10p